Amneal Pharmaceuticals Inc Stock Price, News & Analysis

Amneal Pharmaceuticals (NYSE: AMRX) will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company. Mr. Patel will also host a fireside chat at 11:45 AM ET. Investors can access a live webcast from the Investor Relations section of Amneal's website, with a replay available for 90 days post-event.

Amneal is based in Bridgewater, NJ, and focuses on developing, manufacturing, and distributing around 270 generic and specialty pharmaceuticals in the U.S. The company is expanding its Generics segment with complex products and has a robust portfolio in Specialty pharmaceuticals aimed at addressing unmet medical needs.

Amneal Pharmaceuticals (NYSE: AMRX) reported preliminary financial results for Q1 2023, expecting net revenues of $550 million to $560 million, reflecting a 12% increase compared to Q1 2022. Loss before income taxes improved to between $10 million and $0, marking a 50% enhancement year-over-year. Adjusted EBITDA is anticipated to be between $115 million and $120 million, up 18% from the previous year. As of March 31, 2023, long-term debt stood at $2.692 billion, with cash reserves of $151 million, lowering net debt to $2.541 billion. The company reaffirmed its full-year guidance, maintaining projected net revenues of $2.25 billion to $2.35 billion.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2023 financial results on May 5, 2023, before market open. The company will host a conference call at 8:30 a.m. ET on the same day. Interested parties can access the live webcast through the Investor Relations section of their website.

For conference call access, dial 1 (833) 470-1428 in the U.S.; international numbers are available via a provided link. The access code for the call is 957420. A replay will be available for seven days at 1 (866) 813-9403, with the access code 704782.

Amneal, based in Bridgewater, NJ, offers a wide range of generic and specialty pharmaceuticals, focusing on complex product categories and unmet medical needs.

Amneal Pharmaceuticals (NYSE: AMRX) announced that the FDA has accepted its ANDA for a 4mg naloxone hydrochloride nasal spray, a generic version of Narcan, used for opioid overdose treatment. This product addresses the opioid crisis, with annual U.S. sales reaching $318 million as of December 2022, according to IQVIA. The company plans to launch the product at a significant scale, enhancing access to this essential medication. Amneal is committed to expanding its portfolio within the pharmaceutical sector, focusing on complex generics and specialty drugs.

Amneal Pharmaceuticals (AMRX) reported Q4 2022 net revenue of $610 million, up 14% year-over-year, driven by new Generic launches and Specialty products. Despite a net loss of $4 million for Q4, adjusted net income was $71 million, highlighting operational improvements. For the full year, revenue reached $2.21 billion, a 6% increase, but the company faced a net loss of $130 million, largely due to a $263 million anti-trust settlement. For 2023, Amneal guides net revenue of $2.25 to $2.35 billion and adjusted EBITDA of $500 to $530 million.

Amneal Pharmaceuticals (NYSE: AMRX) will announce its fourth quarter and full year 2022 financial results on March 2, 2023, before the market opens. A conference call and live webcast will take place at 8:30 a.m. Eastern Time on the same day. Investors can access the call via the Investor Relations section of the company's website here. To join the call, U.S. callers can dial 1 (844) 200-6205 and international callers 1 (929) 526-1599, using the access code 477511. A replay will be available for seven days following the call.

Amneal Pharmaceuticals (NYSE: AMRX) has entered a long-term licensing agreement with Orion Corporation to commercialize complex generic products in Europe, Australia, and New Zealand. This collaboration marks a significant step in Amneal's strategic priority for international expansion. The initial portfolio will consist of existing generic products available in the U.S. and selected pipeline products, with registrations starting in 2023. Financial terms of the deal were not disclosed, but both companies express optimism about the partnership's potential in the second-largest pharmaceutical market.

Amneal Pharmaceuticals (NYSE: AMRX) reported a successful year in 2022, launching 26 new generic products, with 8 in Q4 alone, including clindamycin phosphate gel and ipratropium bromide nasal sprays. The company received FDA approval for its first large volume bag product, esmolol hydrochloride in sodium chloride injection, expected to generate annual sales of $57 million. For 2023, Amneal anticipates over 30 new product launches, signaling ongoing innovation and growth in its injectables business.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced its participation in two upcoming investor conferences. The Piper Sandler 34th Annual Healthcare Conference will be held on December 1, 2022 in New York, while the 41st Annual J.P. Morgan Healthcare Conference is scheduled for January 10, 2023 in San Francisco, with a presentation at 2:15 PM PT. A live webcast of the J.P. Morgan presentation will be available on the company's website, with a replay accessible for 90 days.

Amneal is a fully integrated essential medicines company based in Bridgewater, NJ, focusing on generic and specialty pharmaceuticals.